Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Br J Haematol. 2018 Mar 12;181(1):111–121. doi: 10.1111/bjh.15157

Figure 4. Urinary and Plasma Biomarkers in sickle cell neuropathy.

Figure 4

After 8 weeks of Atorvastatin treatment, sickle cell mice demonstrated significant decrease in KIM-1, *p<0.05 (A) without seeing significant changes in urine (Ur) Nephrin and NGAL (B and C). SS mice have elevated levels of Ur KIM-1 and Ur Nephrin (A and B), *p<0.05. C. Plasma (Pla) sVCAM1 is elevated in SS mice, ***p<0.001. After 8 weeks of statin treatment there is a significant decrease in plasma sVCAM1, **p<0.01.